ERBB2 and neoplasm: In this review, we discuss current predictive biomarkers for mCRC patients and their associated targeted therapy, including emerging parameters for anti-EGFR agents, such as primary tumor sidedness and longitudinal follow-up using circulating tumor DNA (ctDNA), immune checkpoint inhibitors for MSI/dMMR tumors, new developments for BRAFV600E-mutated cancers, anti-HER2 treatments and NTRK inhibitors.